Pfizer Inc. (NYSE:PFE) Receives $28.06 Consensus Target Price from Brokerages

Pfizer Inc. (NYSE:PFE) has been given a consensus rating of “Hold” by the nineteen research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $28.0588.

Several brokerages recently commented on PFE. HSBC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Finally, Morgan Stanley lowered their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th.

Pfizer Stock Up 0.7%

Pfizer stock opened at $25.05 on Friday. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69. The business has a fifty day moving average price of $25.15 and a 200-day moving average price of $24.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market capitalization of $142.40 billion, a price-to-earnings ratio of 14.56 and a beta of 0.46.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s payout ratio is 100.00%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of PFE. Norges Bank purchased a new position in Pfizer during the second quarter valued at approximately $2,270,157,000. Amundi grew its stake in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Vanguard Group Inc. increased its holdings in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Finally, Neuberger Berman Group LLC boosted its holdings in Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after buying an additional 6,045,763 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.